OMRON Healthcare Receives Breakthrough FDA De Novo Clearance for Advanced Blood Pressure Monitors with AI-Driven AFib Detection

OMRON Healthcare has received De Novo authorisation from the U.S. Food and Drug Administration (FDA) to market its innovative home blood pressure monitors featuring artificial intelligence (AI)-based atrial fibrillation (AFib) detection technology. 

This marks a significant advancement in addressing the increasing prevalence of AFib, a leading cause of stroke.

The new devices integrate OMRON’s IntelliSense™ AFib algorithm, which uses machine learning to analyse the Pressure Pulse Wave during blood pressure measurement. 

This technology enables the detection of AFib with high precision, facilitating early identification of this potentially serious condition.

The FDA's De Novo classification process was employed for this approval, highlighting the monitors as novel devices with no prior equivalent on the market. 

This pathway is increasingly utilised for digital health innovations, particularly those incorporating AI technologies.

AFib is the most common type of heart arrhythmia and is associated with serious health risks, including stroke, heart failure, and chronic kidney disease. Many individuals remain unaware of their condition, as nearly 40% of cases are asymptomatic.

Clinical studies have demonstrated the reliability of OMRON’s IntelliSense™ AFib algorithm, with findings showing 95% sensitivity and 98% specificity for detecting AFib.

Source: https://www.prnewswire.com/news-releases/fda-grants-de-novo-authorization-to-omron-healthcare-for-new-blood-pressure-monitors-with-ai-powered-afib-detection-feature-302306121.html